# Sermorelin Effects, Side Effects & Safety: What the Record Shows > Sermorelin effects and side effects, graded honestly: the GH and IGF-1 changes the studies measured, what research-use communities report, and the cited cautions that matter. ## The short version This page separates three things people usually blur together: what sermorelin studies actually measured, what users in research communities report, and what the cited cautions are. Sermorelin raises the body's own growth hormone and IGF-1 — that part is well documented [2][3]. The downstream adult benefits people hope for (better sleep, fat loss, recovery) are far less proven, and some of the most-cited effects belong to a related drug, tesamorelin, not to sermorelin itself [7]. The honest summary: the GH/IGF-1 signal is real and short-lived per dose; the long-term adult safety record is thin [5]; and because growth hormone and IGF-1 promote cell growth, there is a recognized theoretical caution for anyone with cancer concerns [9]. None of the below is dosing advice — it is a reading of the literature and a clearly-labeled note of what the community reports. ## What the studies measured These are cited, study-attributed effects — the measured ones, not anecdotes. - **Growth in deficient children.** Once-daily subcutaneous GHRH(1-29) raised first-year height velocity from about 4.1 to roughly 7-8 cm/year in growth-hormone-deficient children, without excessive IGF-1 generation [1]. - **Restored GH/IGF-1 in older men.** Two weeks of twice-daily subcutaneous GHRH(1-29) produced dose-related increases in 24-hour GH and IGF-1; at the high dose, those markers no longer differed from young men, with no change in fasting glucose [2]. - **Reliable GH release, short duration per dose.** Intravenous GHRH(1-29)NH2 released GH at doses as low as 0.25 mcg/kg and kept GH elevated for about three hours despite rapid clearance [3]. - **Cognition signal — but from a different analog.** A randomized, placebo-controlled trial in 152 older adults used the stabilized GHRH analog tesamorelin (1 mg/day for 20 weeks), not sermorelin, and found a favorable effect on cognition (P=0.03), a 117% IGF-1 rise within the physiologic range, and a 7.4% drop in body fat [7]. Attributing those body-composition and cognition numbers to sermorelin itself is a common misread. ## What people report These are effects described in research-use communities — **anecdotal, not clinical evidence**, not verified by controlled trials, and not attached to any dose here. Frequently reported on the upside: better-quality or deeper sleep (which fits the biology, since GH is released during slow-wave sleep), gradual changes in recovery, and a slow onset measured in weeks-to-months rather than days. Occasionally reported: improved skin or a sense of better body composition over a long run. Reported downsides and frustrations: injection-site redness or itching; flushing or a head-rush shortly after a dose; for some, the opposite of better sleep — feeling wired or waking up — which is exactly the kind of individual variation a controlled trial would average out. Research-user communities also widely report that oral, sublingual, and troche "sermorelin" products feel ineffective; that complaint is consistent with the very low intranasal bioavailability (~3-5%) seen for GHRH(1-29) in pharmacokinetic work [3]. Treat all of this as signal to investigate, not proof of anything. ## Safety & cautions Each caution below is grounded in the cited literature or in mechanism, and theoretical risks are labeled as theoretical. - **Adult anti-aging use is not established.** An Annals of Internal Medicine editorial judged the use of GH secretagogues to prevent or treat aging "not yet ready for prime time" — the evidence does not yet justify it [5]. Long-term tolerability data for adult anti-aging use specifically remain limited [5]. - **GH/IGF-1 and cancer — a theoretical caution.** Growth hormone and IGF-1 are mitogenic (they promote cell growth), so chronically raising them is theorized to carry oncologic risk. This is a recognized safety consideration for any GH-axis intervention, even though sermorelin acts through the body's own feedback-regulated pulsatile secretion [9]. It is a mechanistic concern, not a demonstrated clinical finding for sermorelin. - **Frontier oncology results cut both ways and are not clinical.** The in-silico glioma signal is a computational drug-repurposing prediction, not evidence that sermorelin is safe or effective in cancer [9]. It should not reassure or alarm a reader about human use. - **Prohibited in sport.** GHRH analogs are on the WADA Prohibited List (S2), with validated detection methods; athletes face anti-doping consequences. (Research-context note, not medical advice.) - **Glucose was unaffected in the older-men study**, which is reassuring as far as it goes [2] — but a 14-day study is not a long-term safety record. --- An engineering-datasheet reading of the sermorelin record — every GHRH(1-29) figure logged to its study and stamped with an evidence grade, the proven pediatric trial kept apart from the borrowed tesamorelin numbers and both apart from the in-silico oncology and preclinical regenerative signals; no clinic behind the spec sheet and nothing here dosed, compounded, prescribed, or sold.